Skip to content

Why Is The Internet Buzzing About Pfizer And Protalix BioTherapeutics’ Orphan Drug Elelyso For Gaucher Disease ?

November 13, 2012

         Per a November 13, 2012, article in Globes [online] (Israel’s Business News), it is reported that Pfizer and Protalix BioTherapeutics is close to signing an agreement for selling Elelyso to the government of Brazil. The deal may be worth hundreds of millions of dollars. Pfizer and Protalix BioTherapeutics are negotiating with the Brazilian government and that an agreement “  ….. would probably be signed within a few days”.    

         Both pharmaceutical companies divide the revenue and responsibilities for Elelyso : 

–  60% of revenue to Pfizer

–  40% of revenue to Protalix BioTherapeutics

–  Pfizer is responsible for marketing and marketing expenses

–  Protalix BioTherapeutics is responsible for production and ancillary expenses.

    The Orphan Druganaut Blog will report additional information on this topic as it becomes available.

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: